This highlights the possibility that the heterogeneity within TSC and S-LAM patients is predominantly dictated by the cells that carry a first-hit TSC gene mutation and, consequently, the resulting progeny left vulnerable to acquiring a second-hit mutation. The gene discussed is SLC12A3; the disease is lymphangioleiomyomatosis.